Lineage Cell Therapeutics (LCTX) Misses Q4 EPS by 11c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of ($0.15), $0.11 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $2.57 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Redburn upgrades Southwest, stays bullish on Delta and United
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in